News
VNDA
7.00
-0.99%
-0.07
Vanda Announces Resignation of Senior Legal Executive
TipRanks · 12h ago
Vanda SVP, General Counsel Timothy Williams resigns effective April 10
Reuters · 13h ago
Analysts Offer Insights on Healthcare Companies: Lucid Diagnostics (LUCD), Vanda (VNDA) and Cytokinetics (CYTK)
TipRanks · 3d ago
Weekly Report: what happened at VNDA last week (0323-0327)?
Weekly Report · 4d ago
Weekly Report: what happened at VNDA last week (0316-0320)?
Weekly Report · 03/23 09:14
Vanda Pharmaceuticals Advocates For Stronger FDA Measures To Accelerate Shift From Animal Testing To Human-Relevant Methods
Benzinga · 03/19 20:39
Vanda Pharmaceuticals urges FDA to revise draft guidance on non-animal testing methods
Reuters · 03/19 20:35
EMA: ISSUED ITS OPINION ON HETLIOZ MARKETING AUTHORISATION CHANGE AFTER RE-EXAMINATION ON 16 MARCH
Reuters · 03/17 16:16
EMA: REFUSAL OF CHANGE TO HETLIOZ MARKETING AUTHORISATION TO ADD TREATMENT OF NIGHTTIME SLEEP DISTURBANCE IN ADULTS WITH SMITH-MAGENIS SYNDROME
Reuters · 03/17 16:16
Weekly Report: what happened at VNDA last week (0309-0313)?
Weekly Report · 03/16 09:14
Vanda Advances NEREUS Launch With Direct-to-Consumer Strategy
TipRanks · 03/11 02:27
Weekly Report: what happened at VNDA last week (0302-0306)?
Weekly Report · 03/09 09:14
This Equinix Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 03/05 12:36
Vanda Pharmaceuticals Price Target Announced at $18.00/Share by Truist Securities
Dow Jones · 03/05 11:34
Truist Securities Initiates Coverage On Vanda Pharmaceuticals with Buy Rating, Announces Price Target of $18
Benzinga · 03/05 11:25
Vanda Pharmaceuticals initiated with a Buy at Truist
TipRanks · 03/05 11:11
U.S. RESEARCH ROUNDUP-Broadcom, CNX Resources, Veeva Systems
Reuters · 03/05 07:16
Vanda’s Top Brass Quietly Unload a Wave of Shares in Coordinated Sell-Off
TipRanks · 03/05 02:07
Vanda granted public hearing to review FDA denying Hetlioz for jet lag
Seeking Alpha · 03/03 21:40
AnaptysBio provides update on potential spin-off of biopharma operations
TipRanks · 03/03 21:37
More
Webull provides a variety of real-time VNDA stock news. You can receive the latest news about Vanda Pharma through multiple platforms. This information may help you make smarter investment decisions.
About VNDA
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.